Last €39.77 EUR
Change Today +0.052 / 0.13%
Volume 2.7K
ABL On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
London
Sao Paulo
Frankfurt
As of 3:16 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

abbott laboratories (ABL) Snapshot

Open
€39.67
Previous Close
€39.72
Day High
€40.30
Day Low
€39.48
52 Week High
01/30/15 - €40.30
52 Week Low
02/4/14 - €26.32
Market Cap
59.9B
Average Volume 10 Days
968.9
EPS TTM
€1.60
Shares Outstanding
1.5B
EX-Date
01/13/15
P/E TM
28.0x
Dividend
€0.92
Dividend Yield
1.76%
Current Stock Chart for ABBOTT LABORATORIES (ABL)

abbott laboratories (ABL) Details

Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis or depressive symptoms, gynecological disorders, dyslipidemia, hypertension, hypothyroidism, pain, fever, and inflammation; and regulates physiological rhythm of the colon, as well as provides hormone replacement therapy and anti-infective and influenza vaccines. The company’s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products, such as various forms of prepared infant and follow-on formula. The company’s Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular diseases. Abbott Laboratories also offers blood glucose and glucose monitoring systems, test strips, and data management software and accessories for people with diabetes; and medical devices for the eye, such as cataract surgery, LASIK surgery, and contact lens care and dry eye products. The company primarily serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. It has strategic alliance with Fonterra Co-operative Group Ltd. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

77,000 Employees
Last Reported Date: 01/29/15
Founded in 1888

abbott laboratories (ABL) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.9M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $969.7K
Executive Vice President, General Counsel and...
Total Annual Compensation: $650.0K
Executive Vice President of Diagnostic Produc...
Total Annual Compensation: $614.6K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $629.5K
Compensation as of Fiscal Year 2013.

abbott laboratories (ABL) Key Developments

The U.S. FDA approves Two New TECNIS® Multifocal Intraocular Lenses Developed by Abbott

The U.S. FDA approved Two New TECNIS® Multifocal Intraocular Lenses. Two new intraocular lenses (IOLs) that restore vision to people with cataracts are now available in the United States. The new TECNIS® Multifocal IOLs, developed by Abbott, provide people with cataracts options to have a full range of near, intermediate and distance vision, while customizing their treatment based on their personal vision needs and lifestyle. Cataract surgery is one of the most common and safest procedures in the United States, with more than three million surgeries done each year. That number is expected to grow as the population gets older, and as some people choose to have cataract surgery sooner in life, given new technologies becoming available that can significantly improve vision. An IOL is an artificial lens placed in a person's eye to restore vision after a cataract has been removed. While traditional monofocal IOLs are designed to restore far or distance vision, multifocal IOLs provide quality vision at multiple distances and reduce or eliminate the need for glasses. The new lenses approved by the U.S. Food and Drug Administration are known as TECNIS Multifocal +2.75D and +3.25D IOLs. Along with the available TECNIS Multifocal +4.0D IOL, all of the TECNIS Multifocal IOLs provide excellent vision at near, intermediate and far distances, while each "lens power" version provides enhanced vision at a distinct distance. The TECNIS Multifocal +4.0D is suited for people favoring near vision-related activities, such as reading a book. The TECNIS Multifocal +3.25D IOL is suited for people who favor activities at longer reading distances, such as reading a hand-held device like a tablet. The TECNIS Multifocal +2.75D IOL is suited for people who favor activities done with intermediate vision, such as reading labels while grocery shopping. The TECNIS Multifocal IOLs have been well-studied. The FDA approval of the new TECNIS Multifocal +2.75D and +3.25D IOLS is based on a study of 445 people with cataracts. The results showed: more than 80% of people reported being able to function comfortably without glasses at all distances; 93% of patients reported they would have the same IOL implanted again; patients had a mean visual acuity of 20/25 in both eyes at near distances (uncorrected, or without glasses or contact lenses); patients had a mean visual acuity of 20/20 in both eyes at far distances (uncorrected; good vision was maintained in low lighting conditions.

Abbott Laboratories Announces Quarterly Cash Dividend, Payable on February 15, 2015

On Dec. 12, 2014, the board of directors of Abbott Laboratories increased the company's quarterly dividend to $0.24 per share from $0.22 per share. The cash dividend is payable Feb. 15, 2015, to shareholders of record at the close of business on Jan. 15, 2015.

Abbott Laboratories Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter and Full Year of 2015

Abbott Laboratories announced unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported net sales of $5,356 million against $5,072 million a year ago. Operating earnings was $829 million against $627 million a year ago. Earnings from continuing operations before taxes were $804 million against $606 million a year ago. Earnings from continuing operations were $634 million or $0.41 per diluted share against $483 million or $0.31 per diluted share a year ago. Net earnings were $905 million or $0.59 per diluted share against $589 million or $0.37 per diluted share a year ago. Net earnings from continuing operations, excluding specified items were $943 million or $0.62 per diluted share against $754 million or $0.48 per diluted share a year ago. Net earnings excluding specified items of $1,088 million, or $0.71 per share against $918 million or $0.58 per diluted share a year ago. For the year, the company reported Net sales of $20,247 million against $19,657 million a year ago. Operating earnings was $2,599 million against $2,133 million a year ago. Earnings from continuing operations before taxes were $2,518 million against $2,041 million a year ago. Earnings from continuing operations were $1,721 million or $1.12 per diluted share against $1,988 million or $1.26 per diluted share a year ago. Net earnings were $2,284 million or $1.49 per diluted share against $2,576 million or $1.62 per diluted share a year ago. Net earnings from continuing operations, excluding specified items were $3,038 million or $1.98 per diluted share against $2,597 million or $1.64 per diluted share a year ago. Net earnings excluding specified items were $3,503 million or $2.28 per share against $3,189 million or $2.01 per diluted share a year ago. The company issues full-year 2015 guidance for earnings-per-share from continuing operations, excluding specified items, will be $2.10 to $2.20, representing top-tier growth at the mid-point of the guidance range. The company forecasts net specified items for the full year 2015 of approximately $0.77 per share. Specified items include intangible amortization expense, charges associated with cost reduction initiatives and deal and other expenses related to acquisitions. Including net specified items, projected earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) would be $1.33 to $1.43 for the full year 2015. For the full year 2015, the company expects global Medical Optics business to grow mid- to high single digits on an operational basis, with low to mid-single-digit growth in the first quarter. Excluding the contributions from acquisitions made in 2014, the company expects high single-digit operational sales growth in EPD for the full year 2015. The company expects continued strong double-digit growth in EPD on an operational basis, including the impact of acquisitions as this business continues to expand product portfolios in key therapeutic areas, implements new branding initiatives across the portfolio and increases its focus on marketing to the pharmacy channel. The company issues first-quarter 2015 guidance for earnings-per-share guidance from continuing operations, excluding specified items, of $0.41 to $0.43. Abbott forecasts specified items for the first quarter 2015 of $0.23 related to the same items for the full year 2015. Including specified items, projected earnings-per-share from continuing operations under GAAP would be $0.18 to $0.20 for the first quarter. For the first quarter, we're also forecasting strong double-digit growth in EPD on an operational basis, including the impact of acquisitions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABL:GR €39.77 EUR +0.052

ABL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.35 USD -2.77
Actavis plc $266.54 USD -6.71
Danaher Corp $82.38 USD -1.55
Eli Lilly & Co $72.00 USD -0.11
Teva Pharmaceutical Industries Ltd $56.86 USD -0.70
View Industry Companies
 

Industry Analysis

ABL

Industry Average

Valuation ABL Industry Range
Price/Earnings 39.7x
Price/Sales 3.4x
Price/Book -- Not Meaningful
Price/Cash Flow 23.7x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit www.abbott.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.